Researchers are developing a new RNA-based therapy designed to help the heart repair itself after a heart attack, addressing one of cardiology’s most persistent challenges—the heart’s limited ability to regenerate damaged tissue. Even when doctors successfully reopen blocked arteries and restore blood flow, lost heart muscle cells rarely grow back, often leaving patients with permanent damage that can lead to heart failure.
According to Ke Cheng, Alan L. Kaganov Professor of Biomedical Engineering at Columbia Engineering, the heart has very limited regenerative capacity. As a result, many heart attack survivors later develop chronic heart failure due to irreversible muscle loss.
Turning the Body into a Drug Producer
In a study published in Science, Cheng and his research team introduced an innovative therapeutic approach that turns the body into its own drug factory. Instead of delivering medicine directly to the heart, the therapy uses RNA instructions that prompt other tissues to produce a healing molecule.
Clinicians can administer the treatment through a simple injection into the arm, making it far less invasive than traditional procedures such as direct cardiac injections or catheter-based interventions.
Learning from the Regenerative Ability of Newborn Hearts
Interestingly, newborn mammals briefly retain the ability to regenerate heart muscle cells. This process involves a hormone called atrial natriuretic peptide (ANP), which promotes blood vessel growth, reduces inflammation, and limits scar formation.
However, ANP levels decline significantly with age, reducing the heart’s natural repair capacity. Researchers observed that newborn mice increased ANP-related gene activity more than 25-fold after heart injury, whereas adults showed only modest increases.
Encouraging Results in Preclinical Studies
To overcome this limitation, scientists engineered RNA-lipid nanoparticles carrying instructions for the Nppa gene, which produces ANP’s precursor. After injection into skeletal muscle, the cells generate pro-ANP, an inactive molecule that travels through the bloodstream to the heart.
Once it reaches the heart, an enzyme called Corin activates the molecule, triggering repair mechanisms. In preclinical studies, a single injection reduced scar tissue and improved heart function in both small and large animal models.
Future Potential for Regenerative Medicine
As reported by scitechdaily, the researchers also used self-amplifying RNA (saRNA) to extend the therapy’s effect, allowing the treatment to remain active for up to four weeks after a single dose. Furthermore, the therapy showed positive results even when administered days after a heart attack.
If future clinical trials confirm its effectiveness, this strategy could transform the treatment of heart disease and other organ damage, including conditions such as kidney disease, hypertension, and preeclampsia.